BSE: SYNGENE - Syngene International Limited

Yield per half year: -18.52%
Dividend yield: +0.24%

Share chart Syngene International Limited


About Syngene International Limited

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally.

more details
The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

ISIN INE398R01022
Industry Biotechnology
Sector Health Care
Валюта inr
Валюта отчета inr
Див.доход ао 0.2417
Дивиденд ао 1.25
Сайт https://www.syngeneintl.com
Цена ао 720.7
Change price per day: +0.0694% (720.7)
Change price per week: +2.36% (704.55)
Change price per month: +4.66% (689.1)
Change price per 3 month: -14.8% (846.45)
Change price per half year: -18.52% (885.15)
Change price per year: +1.33% (711.75)
Change price per 3 year: +22.47% (588.9)
Change price per 5 year: +131.6% (311.4)
Change price per year to date: -15.95% (858.05)

Underestimation

Title Value Grade
P/S 8.33 1
P/BV 6.59 1
P/E 55 2
EV/EBITDA 23.43 5
Total: 4

Efficiency

Title Value Grade
ROA, % 8.29 3
ROE, % 11.98 4
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0.2417 0.6
DSI 1 10
Total: 3.19

Debt

Title Value Grade
Debt/EBITDA 0.141 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 67.48 8
Yield Ebitda, % 30.38 5
Yield EPS, % 29.09 4
Total: 6.2

Head Job title Payment Year of birth
Mr. Jonathan Brittan Hunt MD, CEO & Executive Director 84.75M 1969 (56 years)
Mr. Sibaji Biswas CFO & Executive Director 34.14M
Krishnan G Head of Investor Relations N/A
Ms. Priyadarshini Mahapatra C.S. Head of Legal, Company Secretary & Compliance Officer 4.72M
Mr. Sandeep Nair Head of Corporate Communications N/A
Mr. Andrew Webster Chief Human Resources Officer N/A
Dr. Dhananjay Patankar Head of Pharmaceutical & Biopharmaceutical Development N/A
Mr. Purushottam Shashikant Singnurkar Head of Formulations Development N/A
Mr. Ajit Manocha Head of IT N/A
Dr. Jayashree Aiyar Ph.D. Head of Discovery Biology N/A

Address: India, Bengaluru, Velankani Technology Park - open in Google maps, open in Yandex maps
Website: https://www.syngeneintl.com